Orchidia Pharmaceutical Industries (“Orchidia”), is the leading Egyptian ophthalmic generic medicine manufacturer and one of the fastest growing pharmaceutical companies in Egypt amongst 45 companies operating in the Egyptian Ophthalmology market. Orchidia operates in 12 therapeutic segments including Artificial Tears & Eye Lubricants, Anti-Glaucoma and Contact Lens Solutions among others, encompassing over 98 eye care products currently registered or under the registration process. Orchidia was initially established as a local agent responsible for marketing and distributing eye care and general medicine products for numerous multinational pharmaceutical companies up until 2002. In 2003, the Company expanded its services from being a marketing service provider to a local manufacturer with the goal of producing affordable quality eye care products. In 2005, Orchidia began constructing its own manufacturing facility in Al-Obour city’s industrial area which commenced operations in 2009.

In November 2017, the Egyptian-American Enterprise Fund (“EAEF”), under LCP’s management, announced the acquisition of a significant minority stake in Orchidia Pharmaceutical Industries. The transaction consisted of a capital increase in addition to acquiring the stake owned by SPE Capital, formerly Swicorp Private Equity as well as a stake owned by the other shareholders.

Visit the company’s website http://orchidiapharma.com